Boston Scientific is growing its urology portfolio with a $3.7 billion deal to acquire Axonics, makers of neurostimulation therapies for urinary and fecal incontinence. Currently a chief competitor in ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Axonics today announced its R20 rechargeable sacral neuromodulation (SNM) system has received CE Mark approval for use in adults with overactive bladder and/or fecal incontinence. The implant can last ...

Boston Scientific has closed on its $3.7 billion acquisition of Axonics. The Marlborough, MA-based company first announced the deal in January. Axonics develops devices to treat urinary and bowel ...

“I am grateful for Eileen’s leadership as interim CEO, and the continued dedication of Paula Newell, founder & board director ...